Third Rock Pumps $41 Million Into Global Blood Therapeutics
In the firm’s largest solo investment ever, Third Rock backed a new platform company that will seek to identify and develop a pipeline of drugs for rare blood disorders.
In the firm’s largest solo investment ever, Third Rock backed a new platform company that will seek to identify and develop a pipeline of drugs for rare blood disorders.